JP2012503009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012503009A5 JP2012503009A5 JP2011527994A JP2011527994A JP2012503009A5 JP 2012503009 A5 JP2012503009 A5 JP 2012503009A5 JP 2011527994 A JP2011527994 A JP 2011527994A JP 2011527994 A JP2011527994 A JP 2011527994A JP 2012503009 A5 JP2012503009 A5 JP 2012503009A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- compound according
- pharmaceutically acceptable
- acceptable salt
- seizures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 29
- 208000002193 Pain Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 11
- 206010010904 Convulsion Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 5
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000000155 isotopic effect Effects 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010064012 Central pain syndrome Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 208000022540 Consciousness disease Diseases 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 claims description 3
- 208000002091 Febrile Seizures Diseases 0.000 claims description 3
- 206010019468 Hemiplegia Diseases 0.000 claims description 3
- 208000004404 Intractable Pain Diseases 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 206010029350 Neurotoxicity Diseases 0.000 claims description 3
- 206010031009 Oral pain Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 3
- 208000009205 Tinnitus Diseases 0.000 claims description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 3
- 230000001037 epileptic effect Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 231100000228 neurotoxicity Toxicity 0.000 claims description 3
- 230000007135 neurotoxicity Effects 0.000 claims description 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 3
- 230000002889 sympathetic effect Effects 0.000 claims description 3
- 231100000886 tinnitus Toxicity 0.000 claims description 3
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010013952 Dysphonia Diseases 0.000 claims description 2
- 208000032274 Encephalopathy Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 206010006542 Bulbar palsy Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 201000002241 progressive bulbar palsy Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 description 4
- 125000004431 deuterium atom Chemical group 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 206010054196 Affect lability Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical group C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 210000001184 pharyngeal muscle Anatomy 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960004482 quinidine sulfate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9851108P | 2008-09-19 | 2008-09-19 | |
| US61/098,511 | 2008-09-19 | ||
| PCT/US2009/057476 WO2010033801A1 (en) | 2008-09-19 | 2009-09-18 | Morphinan compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015078415A Division JP6047620B2 (ja) | 2008-09-19 | 2015-04-07 | モルヒナン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012503009A JP2012503009A (ja) | 2012-02-02 |
| JP2012503009A5 true JP2012503009A5 (enExample) | 2012-11-01 |
| JP5730769B2 JP5730769B2 (ja) | 2015-06-10 |
Family
ID=41213342
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527994A Active JP5730769B2 (ja) | 2008-09-19 | 2009-09-18 | モルヒナン化合物 |
| JP2015078415A Expired - Fee Related JP6047620B2 (ja) | 2008-09-19 | 2015-04-07 | モルヒナン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015078415A Expired - Fee Related JP6047620B2 (ja) | 2008-09-19 | 2015-04-07 | モルヒナン化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (9) | US8710072B2 (enExample) |
| EP (5) | EP2334678B1 (enExample) |
| JP (2) | JP5730769B2 (enExample) |
| KR (2) | KR101761427B1 (enExample) |
| CN (1) | CN102197037B (enExample) |
| AU (1) | AU2009293123B2 (enExample) |
| BR (1) | BRPI0918760A2 (enExample) |
| CA (1) | CA2737811C (enExample) |
| DK (2) | DK3248978T3 (enExample) |
| EA (3) | EA019343B1 (enExample) |
| ES (4) | ES2750825T3 (enExample) |
| MX (2) | MX2011002994A (enExample) |
| PH (1) | PH12013501341B1 (enExample) |
| PL (3) | PL3248978T3 (enExample) |
| PT (2) | PT2418211E (enExample) |
| SI (1) | SI2334678T1 (enExample) |
| WO (1) | WO2010033801A1 (enExample) |
| ZA (1) | ZA201102113B (enExample) |
Families Citing this family (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9867530B2 (en) | 2006-08-14 | 2018-01-16 | Volcano Corporation | Telescopic side port catheter device with imaging system and method for accessing side branch occlusions |
| EP3093290B1 (en) | 2007-05-01 | 2018-01-24 | Concert Pharmaceuticals Inc. | Morphinan compounds |
| ES2401892T3 (es) | 2007-05-01 | 2013-04-25 | Concert Pharmaceuticals Inc. | Compuestos morfinanos |
| US10219780B2 (en) | 2007-07-12 | 2019-03-05 | Volcano Corporation | OCT-IVUS catheter for concurrent luminal imaging |
| EP2178442B1 (en) | 2007-07-12 | 2017-09-06 | Volcano Corporation | Catheter for in vivo imaging |
| US9596993B2 (en) | 2007-07-12 | 2017-03-21 | Volcano Corporation | Automatic calibration systems and methods of use |
| ES2750825T3 (es) | 2008-09-19 | 2020-03-27 | Concert Pharmaceuticals Inc | Compuestos de morfinano deuterados |
| US8829020B2 (en) | 2009-07-16 | 2014-09-09 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| US11141063B2 (en) | 2010-12-23 | 2021-10-12 | Philips Image Guided Therapy Corporation | Integrated system architectures and methods of use |
| US11040140B2 (en) | 2010-12-31 | 2021-06-22 | Philips Image Guided Therapy Corporation | Deep vein thrombosis therapeutic methods |
| WO2013033592A1 (en) | 2011-08-31 | 2013-03-07 | Volcano Corporation | Optical-electrical rotary joint and methods of use |
| CN102731399B (zh) * | 2012-07-06 | 2013-11-06 | 启东东岳药业有限公司 | 高纯度3-甲氧基-9α,13α,14α吗啡喃盐酸盐的制备方法 |
| US9367965B2 (en) | 2012-10-05 | 2016-06-14 | Volcano Corporation | Systems and methods for generating images of tissue |
| US9858668B2 (en) | 2012-10-05 | 2018-01-02 | Volcano Corporation | Guidewire artifact removal in images |
| US10070827B2 (en) | 2012-10-05 | 2018-09-11 | Volcano Corporation | Automatic image playback |
| US9286673B2 (en) | 2012-10-05 | 2016-03-15 | Volcano Corporation | Systems for correcting distortions in a medical image and methods of use thereof |
| US9292918B2 (en) | 2012-10-05 | 2016-03-22 | Volcano Corporation | Methods and systems for transforming luminal images |
| US10568586B2 (en) | 2012-10-05 | 2020-02-25 | Volcano Corporation | Systems for indicating parameters in an imaging data set and methods of use |
| US9324141B2 (en) | 2012-10-05 | 2016-04-26 | Volcano Corporation | Removal of A-scan streaking artifact |
| US11272845B2 (en) | 2012-10-05 | 2022-03-15 | Philips Image Guided Therapy Corporation | System and method for instant and automatic border detection |
| US9307926B2 (en) | 2012-10-05 | 2016-04-12 | Volcano Corporation | Automatic stent detection |
| US20140100454A1 (en) | 2012-10-05 | 2014-04-10 | Volcano Corporation | Methods and systems for establishing parameters for three-dimensional imaging |
| US9478940B2 (en) | 2012-10-05 | 2016-10-25 | Volcano Corporation | Systems and methods for amplifying light |
| US9840734B2 (en) | 2012-10-22 | 2017-12-12 | Raindance Technologies, Inc. | Methods for analyzing DNA |
| EP2931132B1 (en) | 2012-12-13 | 2023-07-05 | Philips Image Guided Therapy Corporation | System for targeted cannulation |
| US10942022B2 (en) | 2012-12-20 | 2021-03-09 | Philips Image Guided Therapy Corporation | Manual calibration of imaging system |
| US10939826B2 (en) | 2012-12-20 | 2021-03-09 | Philips Image Guided Therapy Corporation | Aspirating and removing biological material |
| US11406498B2 (en) | 2012-12-20 | 2022-08-09 | Philips Image Guided Therapy Corporation | Implant delivery system and implants |
| CA2895502A1 (en) | 2012-12-20 | 2014-06-26 | Jeremy Stigall | Smooth transition catheters |
| CA2895989A1 (en) | 2012-12-20 | 2014-07-10 | Nathaniel J. Kemp | Optical coherence tomography system that is reconfigurable between different imaging modes |
| WO2014113188A2 (en) | 2012-12-20 | 2014-07-24 | Jeremy Stigall | Locating intravascular images |
| US10413317B2 (en) | 2012-12-21 | 2019-09-17 | Volcano Corporation | System and method for catheter steering and operation |
| JP2016501623A (ja) | 2012-12-21 | 2016-01-21 | アンドリュー ハンコック， | 画像信号のマルチ経路処理のためのシステムおよび方法 |
| JP2016501625A (ja) | 2012-12-21 | 2016-01-21 | ジェローム マイ， | 可変線密度での超音波撮像 |
| CA2895993A1 (en) | 2012-12-21 | 2014-06-26 | Jason Spencer | System and method for graphical processing of medical data |
| US10058284B2 (en) | 2012-12-21 | 2018-08-28 | Volcano Corporation | Simultaneous imaging, monitoring, and therapy |
| CA2896004A1 (en) | 2012-12-21 | 2014-06-26 | Nathaniel J. Kemp | Power-efficient optical buffering using optical switch |
| CA2896006A1 (en) | 2012-12-21 | 2014-06-26 | David Welford | Systems and methods for narrowing a wavelength emission of light |
| US9612105B2 (en) | 2012-12-21 | 2017-04-04 | Volcano Corporation | Polarization sensitive optical coherence tomography system |
| WO2014100606A1 (en) | 2012-12-21 | 2014-06-26 | Meyer, Douglas | Rotational ultrasound imaging catheter with extended catheter body telescope |
| US9486143B2 (en) | 2012-12-21 | 2016-11-08 | Volcano Corporation | Intravascular forward imaging device |
| CN103044327B (zh) * | 2013-01-07 | 2014-12-17 | 苏州立新制药有限公司 | 一种右美沙芬的制备方法 |
| WO2014117089A1 (en) * | 2013-01-25 | 2014-07-31 | Case Western Reserve University | Compositions and methods for the treatment of pervasive development disorders |
| AU2014212487C1 (en) * | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| CN103073494B (zh) * | 2013-02-04 | 2015-10-07 | 苏州立新制药有限公司 | ent-3-甲氧基吗喃的制备方法 |
| WO2014138555A1 (en) | 2013-03-07 | 2014-09-12 | Bernhard Sturm | Multimodal segmentation in intravascular images |
| US10226597B2 (en) | 2013-03-07 | 2019-03-12 | Volcano Corporation | Guidewire with centering mechanism |
| US20140276923A1 (en) | 2013-03-12 | 2014-09-18 | Volcano Corporation | Vibrating catheter and methods of use |
| US10638939B2 (en) | 2013-03-12 | 2020-05-05 | Philips Image Guided Therapy Corporation | Systems and methods for diagnosing coronary microvascular disease |
| US9301687B2 (en) | 2013-03-13 | 2016-04-05 | Volcano Corporation | System and method for OCT depth calibration |
| EP2967488B1 (en) | 2013-03-13 | 2021-06-16 | Jinhyoung Park | System for producing an image from a rotational intravascular ultrasound device |
| US11026591B2 (en) | 2013-03-13 | 2021-06-08 | Philips Image Guided Therapy Corporation | Intravascular pressure sensor calibration |
| US10426590B2 (en) | 2013-03-14 | 2019-10-01 | Volcano Corporation | Filters with echogenic characteristics |
| US10219887B2 (en) | 2013-03-14 | 2019-03-05 | Volcano Corporation | Filters with echogenic characteristics |
| US12343198B2 (en) | 2013-03-14 | 2025-07-01 | Philips Image Guided Therapy Corporation | Delivery catheter having imaging capabilities |
| US10292677B2 (en) | 2013-03-14 | 2019-05-21 | Volcano Corporation | Endoluminal filter having enhanced echogenic properties |
| US11058648B2 (en) | 2013-11-05 | 2021-07-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10894046B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10966942B2 (en) | 2019-01-07 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10980800B2 (en) | 2013-11-05 | 2021-04-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20200261431A1 (en) | 2019-01-07 | 2020-08-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10105361B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11020389B2 (en) | 2013-11-05 | 2021-06-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11090300B2 (en) | 2013-11-05 | 2021-08-17 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20160361305A1 (en) | 2013-11-05 | 2016-12-15 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| US10940124B2 (en) | 2019-01-07 | 2021-03-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11065248B2 (en) | 2013-11-05 | 2021-07-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11096937B2 (en) | 2013-11-05 | 2021-08-24 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10898453B2 (en) | 2013-11-05 | 2021-01-26 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20170007558A1 (en) * | 2013-11-05 | 2017-01-12 | Antecip Bioventures Ii Llc | Hydroxybupropion and related compounds as modulators of drug plasma levels |
| US11311534B2 (en) | 2013-11-05 | 2022-04-26 | Antecip Bio Ventures Ii Llc | Bupropion as a modulator of drug activity |
| US10874664B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20200338022A1 (en) | 2019-01-07 | 2020-10-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10881657B2 (en) | 2013-11-05 | 2021-01-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10966974B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11123344B2 (en) | 2013-11-05 | 2021-09-21 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10933034B2 (en) | 2013-11-05 | 2021-03-02 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10874665B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11273133B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10894047B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11253491B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10105327B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
| US11213521B2 (en) | 2013-11-05 | 2022-01-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11291638B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10080727B2 (en) | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10786469B2 (en) | 2013-11-05 | 2020-09-29 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9763932B2 (en) | 2013-11-05 | 2017-09-19 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10813924B2 (en) | 2018-03-20 | 2020-10-27 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
| US11147808B2 (en) | 2013-11-05 | 2021-10-19 | Antecip Bioventures Ii Llc | Method of decreasing the fluctuation index of dextromethorphan |
| US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10512643B2 (en) | 2013-11-05 | 2019-12-24 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10688066B2 (en) | 2018-03-20 | 2020-06-23 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
| US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11253492B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
| US10945973B2 (en) | 2013-11-05 | 2021-03-16 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11141416B2 (en) | 2013-11-05 | 2021-10-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9402843B2 (en) | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| US11273134B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9968568B2 (en) * | 2013-11-05 | 2018-05-15 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11123343B2 (en) | 2013-11-05 | 2021-09-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10874663B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11185515B2 (en) | 2013-11-05 | 2021-11-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11234946B2 (en) | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10864209B2 (en) | 2013-11-05 | 2020-12-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10772850B2 (en) | 2013-11-05 | 2020-09-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10799497B2 (en) | 2013-11-05 | 2020-10-13 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20220233470A1 (en) | 2013-11-05 | 2022-07-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11285146B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11129826B2 (en) | 2013-11-05 | 2021-09-28 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| US10966941B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llp | Bupropion as a modulator of drug activity |
| US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20160324807A1 (en) | 2013-11-05 | 2016-11-10 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11007189B2 (en) | 2013-11-05 | 2021-05-18 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| KR20170052684A (ko) * | 2014-09-14 | 2017-05-12 | 아바니르 파마슈티컬스, 인코포레이티드 | 치매에서의 초조함을 치료하기 위한 덱스트로메토르판 화합물 및 퀴니딘을 포함하는 약제학적 조성물 |
| US20180243290A1 (en) * | 2015-07-30 | 2018-08-30 | Concert Pharmaceuticals, Inc. | Morphinan compounds for treating agitation |
| US20180243291A1 (en) * | 2015-07-30 | 2018-08-30 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for treating agitation |
| US20180243289A1 (en) * | 2015-07-30 | 2018-08-30 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for treating agitation |
| JP6694216B2 (ja) | 2015-10-14 | 2020-05-13 | 学校法人 久留米大学 | グレリンを有効成分として含有するレット症候群（ｒｔｔ）の予防・治療剤 |
| WO2017093354A1 (en) | 2015-11-30 | 2017-06-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nmdar antagonists for the treatment of diseases associated with angiogenesis |
| CN105712994B (zh) * | 2016-03-30 | 2017-05-10 | 中国医学科学院药物研究所 | 咪唑酮‑吗啡喃及其制备方法和应用 |
| ES2925277T3 (es) | 2016-07-04 | 2022-10-14 | Avanir Pharmaceuticals Inc | Métodos para la síntesis de dextrometorfano deuterado |
| US20200276186A1 (en) * | 2017-11-20 | 2020-09-03 | Phoenix Pharmalabs, Inc. | Use of morphinans for treating cocaine addiction, pruritis, and seizure disorders |
| US10925842B2 (en) | 2019-01-07 | 2021-02-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| CN110143921A (zh) * | 2019-06-30 | 2019-08-20 | 上海葆隆生物科技有限公司 | 一种氢溴酸右美沙芬氮氧化物杂质的制备方法 |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US11535596B2 (en) * | 2020-08-28 | 2022-12-27 | Center For Neurologic Study | Analogs of dextromethorphan with balanced receptor activities |
| CN114409597B (zh) * | 2022-01-04 | 2023-10-03 | 广东克冠达医药科技有限公司 | 一种青藤碱衍生物及其制备方法与应用 |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB713146A (en) | 1951-10-18 | 1954-08-04 | Roche Products Ltd | Anti-cough agents comprising (ú½)-3-hydroxy-n-methyl-morphinane ethers and process for the manufacture thereof |
| US4316888A (en) | 1980-04-15 | 1982-02-23 | Nelson Research & Development Co. | Method and composition of reducing pain |
| US4446140A (en) | 1981-12-10 | 1984-05-01 | Nelson Research & Development Company | Method and composition for treating mouth pain |
| JPS6089474A (ja) | 1983-10-20 | 1985-05-20 | Toyo Pharma- Kk | モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤 |
| US4694010A (en) | 1985-08-16 | 1987-09-15 | New York University | Anticonvulsant compositions and method |
| US4898860A (en) | 1985-08-16 | 1990-02-06 | New York University | Anticonvulsant composition and method |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
| US5350756A (en) | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| US5366980A (en) | 1991-06-17 | 1994-11-22 | Smith Richard A | Use of dextromethorphan and an oxidase inhibitor to treat dermatitis |
| US5336980A (en) | 1992-12-10 | 1994-08-09 | Leopold Kostal Gmbh & Co. | Apparatus and method for controlling a windshield wiping system |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| JP3696884B2 (ja) * | 1994-03-25 | 2005-09-21 | アイソテクニカ、インコーポレーテッド | ジュウテリウム化による薬物の効能の増強 |
| USRE38115E1 (en) | 1994-09-22 | 2003-05-06 | Center For Neurologic Study | Dextromethorphan and an oxidase inhibitor for treating intractable conditions |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6197830B1 (en) | 1995-09-22 | 2001-03-06 | Bruce M. Frome | Method for achieving relief from sympathetically mediated pain |
| CH690817A5 (de) | 1996-09-03 | 2001-01-31 | Flachsmann Ag Emil | Verfahren zur Herstellung eines stabilen, homogenen, von Folgeprodukten freien oder nahezu freien Extraktes. |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| EP1104760B1 (en) * | 1999-12-03 | 2003-03-12 | Pfizer Products Inc. | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| WO2001041707A2 (en) | 1999-12-08 | 2001-06-14 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
| US20050129783A1 (en) | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
| US6780871B2 (en) | 2001-01-29 | 2004-08-24 | Albany Medical College | Methods and compositions for treating addiction disorders |
| US20040087479A1 (en) | 2001-04-30 | 2004-05-06 | Sosnowski Robert E. | Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases |
| US6583152B2 (en) | 2001-04-30 | 2003-06-24 | Dexgen Pharmaceuticals, Inc. | Composition for reducing the risk or progression of cardiovascular diseases |
| CN1255185C (zh) | 2001-05-03 | 2006-05-10 | 弗·哈夫曼-拉罗切有限公司 | 无定形甲磺酸奈非那韦的药物剂型 |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US7501433B2 (en) * | 2002-05-17 | 2009-03-10 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| CN103405431B (zh) * | 2002-05-17 | 2016-04-13 | 台湾J药品有限公司 | 阿片和阿片样化合物及其用途 |
| TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| DE102004009445A1 (de) | 2004-02-27 | 2005-09-29 | Chemetall Gmbh | Verfahren zur Herstellung von Alkyllithiumverbindungen und Aryllithiumverbindungen durch Reaktionsverfolgung mittels IR-Spektroskopie |
| AU2005244401B2 (en) * | 2004-05-14 | 2009-01-22 | Green Cross Corp. | Neuroprotective properties of dextrorotatory morphinans |
| WO2006039237A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| US20070191411A1 (en) | 2004-10-07 | 2007-08-16 | Smith Richard A | Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor |
| US7114547B2 (en) | 2005-01-11 | 2006-10-03 | Sullivan Michael R | Casting ring |
| CA2624179A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| KR20080097443A (ko) | 2006-02-03 | 2008-11-05 | 아바니르 파마슈티컬스 | 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물 |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| CA2661404A1 (en) | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| ES2401892T3 (es) * | 2007-05-01 | 2013-04-25 | Concert Pharmaceuticals Inc. | Compuestos morfinanos |
| ES2750825T3 (es) * | 2008-09-19 | 2020-03-27 | Concert Pharmaceuticals Inc | Compuestos de morfinano deuterados |
| EP3234274A2 (en) | 2014-12-18 | 2017-10-25 | Armstrong World Industries, Inc. | Integrated ceiling and light system |
| US20180243290A1 (en) | 2015-07-30 | 2018-08-30 | Concert Pharmaceuticals, Inc. | Morphinan compounds for treating agitation |
| US20180243291A1 (en) | 2015-07-30 | 2018-08-30 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for treating agitation |
| US20180243289A1 (en) | 2015-07-30 | 2018-08-30 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for treating agitation |
-
2009
- 2009-09-18 ES ES17179704T patent/ES2750825T3/es active Active
- 2009-09-18 US US13/119,905 patent/US8710072B2/en active Active
- 2009-09-18 PT PT111888483T patent/PT2418211E/pt unknown
- 2009-09-18 DK DK17179704T patent/DK3248978T3/da active
- 2009-09-18 EP EP09792714A patent/EP2334678B1/en not_active Not-in-force
- 2009-09-18 KR KR1020117027474A patent/KR101761427B1/ko not_active Expired - Fee Related
- 2009-09-18 EA EA201170473A patent/EA019343B1/ru not_active IP Right Cessation
- 2009-09-18 EP EP17179704.6A patent/EP3248978B1/en active Active
- 2009-09-18 PL PL17179704T patent/PL3248978T3/pl unknown
- 2009-09-18 CA CA2737811A patent/CA2737811C/en not_active Expired - Fee Related
- 2009-09-18 WO PCT/US2009/057476 patent/WO2010033801A1/en not_active Ceased
- 2009-09-18 PL PL09792714T patent/PL2334678T3/pl unknown
- 2009-09-18 EP EP11188848.3A patent/EP2418211B1/en not_active Not-in-force
- 2009-09-18 ES ES09792714T patent/ES2402088T3/es active Active
- 2009-09-18 AU AU2009293123A patent/AU2009293123B2/en not_active Ceased
- 2009-09-18 BR BRPI0918760A patent/BRPI0918760A2/pt active Search and Examination
- 2009-09-18 EP EP14179393.5A patent/EP2805950B1/en not_active Not-in-force
- 2009-09-18 KR KR1020117008130A patent/KR101716512B1/ko not_active Expired - Fee Related
- 2009-09-18 DK DK11188848.3T patent/DK2418211T3/en active
- 2009-09-18 SI SI200930542T patent/SI2334678T1/sl unknown
- 2009-09-18 EA EA201300869A patent/EA023962B1/ru not_active IP Right Cessation
- 2009-09-18 ES ES14179393.5T patent/ES2656444T3/es active Active
- 2009-09-18 JP JP2011527994A patent/JP5730769B2/ja active Active
- 2009-09-18 PT PT171797046T patent/PT3248978T/pt unknown
- 2009-09-18 MX MX2011002994A patent/MX2011002994A/es active IP Right Grant
- 2009-09-18 MX MX2015007374A patent/MX361542B/es unknown
- 2009-09-18 CN CN200980142670.4A patent/CN102197037B/zh not_active Expired - Fee Related
- 2009-09-18 ES ES11188848.3T patent/ES2575086T3/es active Active
- 2009-09-18 EP EP13169740.1A patent/EP2634187B1/en not_active Not-in-force
- 2009-09-18 PL PL11188848.3T patent/PL2418211T3/pl unknown
- 2009-09-18 EA EA201690033A patent/EA030882B1/ru not_active IP Right Cessation
-
2011
- 2011-03-22 ZA ZA2011/02113A patent/ZA201102113B/en unknown
- 2011-06-08 US US13/155,827 patent/US20120029007A1/en not_active Abandoned
-
2013
- 2013-06-21 PH PH12013501341A patent/PH12013501341B1/en unknown
-
2014
- 2014-03-13 US US14/208,968 patent/US8916582B2/en not_active Expired - Fee Related
- 2014-11-18 US US14/546,173 patent/US9266837B2/en active Active
-
2015
- 2015-04-07 JP JP2015078415A patent/JP6047620B2/ja not_active Expired - Fee Related
- 2015-06-01 US US14/726,758 patent/US9340512B2/en active Active
-
2016
- 2016-05-06 US US15/148,568 patent/US9655895B2/en active Active
-
2017
- 2017-04-14 US US15/488,064 patent/US10022370B2/en active Active
-
2018
- 2018-07-16 US US16/036,164 patent/US10406155B2/en active Active
-
2019
- 2019-07-26 US US16/523,920 patent/US10813926B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012503009A5 (enExample) | ||
| JP2021105032A5 (enExample) | ||
| JP2016199576A5 (enExample) | ||
| Ganesh et al. | Pathophysiology and management of opioid-induced pruritus | |
| JP2013526544A5 (enExample) | ||
| JP2020528430A5 (enExample) | ||
| JP2010535801A5 (enExample) | ||
| JP2017519807A5 (enExample) | ||
| JP2003503450A5 (enExample) | ||
| JP2019534327A5 (enExample) | ||
| US9782404B2 (en) | Methods of treating disease-induced ataxia and non-ataxic imbalance | |
| JP7167236B2 (ja) | せん妄の予防または治療剤 | |
| CN116209657A (zh) | 用于精神障碍或增强的2-氨基茚满化合物 | |
| CN110831584A (zh) | 具有新颖的组合物、组合的靶向药物拯救及其方法 | |
| WO2015093515A1 (ja) | １－インダンスルファミド誘導体を含む疼痛の治療および／または予防剤 | |
| EA200501425A1 (ru) | Арилвинилазациклоалкановые соединения и способы их получения и применения | |
| WO2023186826A1 (en) | 5-meo-dmt for use in the treatment of postpartum depression | |
| JP2018502089A5 (enExample) | ||
| CN103442711A (zh) | 精神分裂症中的认知功能障碍的治疗方法 | |
| WO2009069828A1 (ja) | パーキンソン病の運動合併症または精神症状を改善する薬剤 | |
| JP2007506726A5 (enExample) | ||
| JP2019535715A5 (enExample) | ||
| US20110237597A1 (en) | Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity | |
| JP2005531594A5 (ja) | 慢性痛の治療用トリプルモノアミン再取り込み阻害剤 | |
| JP2010514683A5 (enExample) |